Home > Journals > La Rivista Italiana della Medicina di Laboratorio > Past Issues > La Rivista Italiana della Medicina di Laboratorio 2022 Marzo;18(1) > La Rivista Italiana della Medicina di Laboratorio 2022 Marzo;18(1):11-7

CURRENT ISSUE
 

JOURNAL TOOLS

Publishing options
eTOC
To subscribe
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as
Share

 

ARTICOLO ORIGINALE   

La Rivista Italiana della Medicina di Laboratorio 2022 Marzo;18(1):11-7

DOI: 10.23736/S1825-859X.22.00130-X

Copyright © 2022 EDIZIONI MINERVA MEDICA

language: English

Convalescent plasma in hospitalized patients with COVID-19 pneumonia: a case-control prospective study

Giovanni ROVERONI 1, Lauretta MORO 1, Michela PIVETTA 1, Marina ORFANO 2, Marta SIVIERO 2, Alessia BAGATIN 1, Raffaella BERTI 2, Federico MANENTE 1, Gianluca GESSONI 1, 3

1 Service of Transfusion Medicine, ULSS3 Serenissima, Mestre, Venice, Italy; 2 Service of Transfusion Medicine, ULSS 4 Veneto Orientale, San Donà di Piave, Venice, Italy; 3 Department of Transfusion Medicine of Venice province, Venice, Italy



BACKGROUND: This case-control prospective study aimed to describe the effects of COVID convalescent plasma (CCP) therapy in patients diagnosed with coronavirus disease 2019 (COVID-19) pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, during the fourth trimester of 2020 in Venice Prefecture (North East Italy).
METHODS: Overall, 214 consecutive patients admitted to COVID-19 Hospitals of our district were enrolled. The confirmation of SARS-CoV-2 infection was made through the reverse transcription-polymerase chain reaction test in nasopharyngeal swabs. The severity of each patient’s clinical condition was determined following the Berlin score. The clinical data, laboratory test reports and imaging diagnosis of all patients were analyzed at hospitalization. All subjects were showing symptoms of severe COVID-19 pneumonia and were treated with conventional therapy; 108 patients received standard therapy and 106 received standard therapy in combination with CCP. The endpoint was mortality at 30 days.
RESULTS: The two patient series were comparable for gender, age, risk factors, Berlin score, PaO2/FiO2. Both groups received standard therapy: NSAIDs, ventilator support, LMWH, steroids, antibiotics and antivirals; 106 subjects were additionally administered CCP. The mortality rate at 30 days was 30.6% among subjects treated with standard therapy versus 30.2% among subjects treated with standard therapy plus CCP. Considering the radiological findings and ventilatory support data, it would appear that the disease was more severe in patients treated with ST plus CCP.
CONCLUSIONS: This case-control prospective study showed that in a cohort of hospitalized patients suffering from severe COVID-19 pneumonia, the addition of CCP to the standard therapy did not impact the mortality rate at 30 days. However, we believe that further studies are needed to evaluate the effectiveness of convalescent plasma therapy.


KEY WORDS: COVID-19 serotherapy; Passive immunization; Mortality; Pneumonia; Risk factors

top of page